RetiSpec

RetiSpec Inc. is a medical imaging company developing a tool for the early detection of Alzheimer's disease biomarkers in the eye using machine learning. RetiSpec's test is noninvasive, simple to administer and inexpensive compared to current practices. This advantage of accessible and scalable screening enables widespread early detection of Alzheimer's disease pathology. The company is headquartered in Toronto, and is part of the Ontario Brain Institute (OBI), Biomedical Zone, NEXT Canada, Ontario Centre of Excellence and The Centre for Aging and Brain Health Innovation (CABHI)'s network of companies.